Abstract
Vitamin E deficiency [VED] in exocrine pancreatic insufficiency [EPI] and cholestatic liver disease [CLD] is well documented. In the clinical management of CF patients, high dose oral dl-α-T acetate supplements [α-TS] are routinely used. Yet, no data have been available concerning the need and effectiveness of these supplements.
In 52 CF patients (0.8-27.6 yrs), we investigated the significance of oral α-TS and the contribution of EPI (72 hr fecal fat, coefficient of fat absorption, absorbed fat [AF]), associated CLD (sonography, yGT, AP, serum bile acids) and nutritional status (weight, upper arm circumference [UAC], skinfolds) on α-T status. Fat malabsorption [FMA] was found in 48, CLD in 10, poor fat intake in 28, and malnutrition [UAC] in 9 patients. VED defined by plasma-α-T (1), RBC-α-T (2), and plasma-α-T/cholesterol (3) below the cutoff was found in 45% (1), 17% (2), 42% (3) of group A (50-600 mg/d α-TS, n=36) and 87%, 50%, 71% of group B (no α-TS, n=16), resp. 19%. 83%, 58% of group A had normal α-T, as did 13%, 50%, 29% of group B. There was no correlation between α-T and the total daily dose. α-T of 9 matched pairs (daily α-TS, degree of FMA) with and without CLD, revealed no significant difference. En patients with CLD, a multiplicative relationship (y=axb) between plasma-α-T/cholesterol and γGT was found (slope sign, at p=0.004). No regression model could be fitted for α-T depending on AF. In 2 out of 4 patients with corrected FMA, α-T deficiency was still present. In CF patients, high dose oral α-TS do not protect against α-T deficiency and do not correlate with α-T status. The prevalence of α-T deficiency varies markedly depending on the parameters used to evaluate α-T status. Indication and effectiveness of α-TS in CF patients should be documented. Special attention has to be paid to concomitant factors such as uncorrected FMA and CLD.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Winklhofer-Roob, B., Shmerling, D., Schimek, M. et al. 39 SIGNIFICANCE OF DL-ALPHA-TOCOPHERYL [α-T] ACETATE SUPPLEMENTATION IN PATIENTS WITH CYSTIC FIBROSIS (CF). Pediatr Res 28, 283 (1990). https://doi.org/10.1203/00006450-199009000-00063
Issue date:
DOI: https://doi.org/10.1203/00006450-199009000-00063